Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTQ12RK)

DTT Name	Cytidine deaminase (CDA)
Synonyms	Cytidine aminohydrolase; CDA
Gene Name	CDA
DTT Type	Clinical trial target	[1]
BioChemical Class	Carbon-nitrogen hydrolase
UniProt ID	CDD_HUMAN
TTD ID	T79027
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
EC Number	EC 3.5.4.5
Sequence	MAQKRPACTLKPECVQQLLVCSQEAKKSAYCPYSHFPVGAALLTQEGRIFKGCNIENACY PLGICAERTAIQKAVSEGYKDFRAIAIASDMQDDFISPCGACRQVMREFGTNWPVYMTKP DGTYIVMTVQELLPSSFGPEDLQKTQ
Function	This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.
KEGG Pathway	Pyrimidine metabolism (hsa00240 ) Drug metabolism - other enzymes (hsa00983 ) Metabolic pathways (hsa01100 )
Reactome Pathway	Pyrimidine salvage (R-HSA-73614 ) Neutrophil degranulation (R-HSA-6798695 )
BioCyc Pathway	MetaCyc:HS08334-MON

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tetrahydrouridine	DMR5GSB	Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
------------------------------------------------------------------------------------

The Drug-Metabolizing Enzyme (DME) Role of This DTT

DTT DME Name

Cytidine aminohydrolase (CDA) DME Info

Gene Name

CDA

5 Approved Drug(s) Metabolized by This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[2]
Capecitabine	DMTS85L	Adenocarcinoma	2D40	Approved	[3]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[5]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[6]
------------------------------------------------------------------------------------

References

1	Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One. 2012;7(5):e37424.
2	A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep;22(9):1680-4.
3	Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805.
4	Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74.
5	Tracking decitabine incorporation into malignant myeloid cell DNA in vitro and in vivo by LC-MS/MS with enzymatic digestion. Sci Rep. 2019 Mar 14;9(1):4558.
6	Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol. 2011 Mar;71(3):437-44.